Abstract

In the Balkan and Taiwan, the relationship between exposure to aristolochic acid and risk of urothelial neoplasms was inferred from the A>T genetic hallmark in TP53 gene from malignant cells. This study aimed to characterize the TP53 mutational spectrum in urothelial cancers consecutive to Aristolochic Acid Nephropathy in Belgium. Serial frozen tumor sections from female patients (n = 5) exposed to aristolochic acid during weight-loss regimen were alternatively used either for p53 immunostaining or laser microdissection. Tissue areas with at least 60% p53-positive nuclei were selected for microdissecting sections according to p53-positive matching areas. All areas appeared to be carcinoma in situ. After DNA extraction, mutations in the TP53 hot spot region (exons 5–8) were identified using nested-PCR and sequencing. False-negative controls consisted in microdissecting fresh-frozen tumor tissues both from a patient with a Li-Fraumeni syndrome who carried a p53 constitutional mutation, and from KRas mutated adenocarcinomas. To rule out false-positive results potentially generated by microdissection and nested-PCR, a phenacetin-associated urothelial carcinoma and normal fresh ureteral tissues (n = 4) were processed with high laser power. No unexpected results being identified, molecular analysis was pursued on malignant tissues, showing at least one mutation in all (six different mutations in two) patients, with 13/16 exonic (nonsense, 2; missense, 11) and 3/16 intronic (one splice site) mutations. They were distributed as transitions (n = 7) or transversions (n = 9), with an equal prevalence of A>T and G>T (3/16 each). While current results are in line with A>T prevalence previously reported in Balkan and Taiwan studies, they also demonstrate that multiple mutations in the TP53 hot spot region and a high frequency of G>T transversion appear as a complementary signature reflecting the toxicity of a cumulative dose of aristolochic acid ingested over a short period of time.

Highlights

  • The Aristolochic Acid Nephropathy (AAN) was first reported in the early 1990’s in Belgian patients having undertaken a weightloss regimen contaminated with aristolochic acid (AA) [1,2]

  • G.A, p.R248Q mutation identified by FASAY assay in peripheral blood cells of a patient with LiFraumeni syndrome, this mutation was found in malignant cells from the granulosa cell tumor using DNA extraction, microdissection, nested-PCR and sequencing procedures as used in the present study

  • No artifactual TP53 alterations were found in the various controls carried out to test the occurrence of TP53 DNAinduced damage related to DNA extraction, microdissection, nested-PCR and sequencing procedures

Read more

Summary

Introduction

The Aristolochic Acid Nephropathy (AAN) was first reported in the early 1990’s in Belgian patients having undertaken a weightloss regimen contaminated with aristolochic acid (AA) [1,2]. While the mechanism of AA nephrotoxicity remains to be thoroughly explored, the carcinogenic activity is currently attributed to genotoxicity of AL (aristolactam)-DNA adducts characterized by a high frequency of A.T transversion in the TP53 tumour suppressor gene of AA-associated tumors. This has been well documented in animal experiments [8,9] and, not consistently, in patients showing clinical and histopathological similarities with the original Belgian AAN cases [10,11,12,13,14]. The aim of the present work was to characterize the TP53 mutational spectrum in frozen samples of malignant urothelial tissues from Belgian AAN patients using thoroughly validated genotyping methods

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call